Effects of atorvastatin on nuclear magnetic resonance-defined lipoprotein subclasses and inflammatory markers in patients with hypercholesterolemia

Journal of Atherosclerosis and Thrombosis

Volumn 16, Issue 1, 2009, Pages 51-56

  Ikewaki, Katsunori ^a   Terao, Yoshio ^b   Ozasa, Hideki ^b   Nakada, Yoshinobu ^b   Tohyama, Jun Ichiro ^b   Inoue, Yae ^a   Yoshimura, Michihiro ^b  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Atorvastatin; Inflammatory marker; Nuclear magnetic resonance

Indexed keywords

APOLIPOPROTEIN C3; APOLIPOPROTEIN E; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; LIPOPROTEIN METABOLISM; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE;

EID: 67549085276     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.E563     Document Type: Article

References (16)

1. Expert panel on detectione, and treatment of high blood cholesterol in adults: Excutive summary of the the third report of the national cholesterol education program (NECP) expert panel on dectection, evaluation, and treatment of high bllod cholesterol in adults (adults teatment panel III). JAMA, 2001; 285:2486-2497
2. Pearson TA, Laurora I, Chu H, Kafonek S: The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Archives of Internal Medicine, 2000; 160:459-467
3. Vale MJ, Jelinek MV, Best JD, Health CsgCpoAC: How many patients with coronary heart disease are not achieving their risk-factor targets ? Experience in Victoria 1996-1998 versus 1999-2000. Med J Aust, 2002; 176:211-215
4. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004; 350:1495-1504
5. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, Treating to New Targets (TNT) Investigators: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005; 352:1425-1435
6. Otvos JD: Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clinical Laboratory, 2002; 48:171-180
7. Ikewaki K, Tohyama J, Nakata Y, Wakikawa T, Kido T, Mochizuki S: Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men - a nuclear magnetic resonance study. Journal of Atherosclerosis and Thrombosis, 2004; 11:278-285
8. Ikewaki K, Noma K, Tohyama J, Kido T, Mochizuki S: Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia-a nuclear magnetic resonance study. Int J Cardiol, 2005; 101:441-447
9. Kataoka S, Paidi M, Howard BV: Simplified isoelectric focusing/ immunoblotting determination of apoprotein E phenotype. Clin Chem, 1994; 40:11-13
10. McKenney JM, McCormick LS, Schaefer EJ, Black DM, Watkins ML: Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol, 2001; 88:270-274
11. Soedamah-Muthu SS, Colhoun HM, Thomason MJ, Betteridge DJ, Durrington PN, Hitman GA, Fuller JH, Julier K, Mackness MI, Neil HA, CARDS Investigators: The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis, 2003; 167:243-255
12. Mohammadi A, Macri J, Newton R, Romain T, Dulay D, Adeli K: Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells. Arterioscler Thromb Vasc Biol, 1998; 18:783-793
13. Parhofer KG, Barrett PH, Schwandt P: Atorvastatin improves postprandial lipoprotein metabolism in normolipidemlic subjects. J Clin Endocrinol Metab, 2000; 85:4224-4230
14. Asztalos BF, Roheim PS, Milani RL, Lefevre M, McNamara JR, Horvath KV, Schaefer EJ: Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol, 2000; 20:2670-2676
15. Gordon DJ, Rifkind BM: High-density lipoprotein - the clinical implications of recent studies. N Engl J Med, 1989; 321:1311-1316
16. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH: A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med, 1991; 325:373-381